Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Regeneron Pharmaceuticals, Inc. (NQ: REGN)
263.51 USD  +3.55 (+1.37%)
Streaming Delayed Price  /  Updated: 1:39 PM EDT, May 22, 2013  /  Add to My Watchlist      
View: Quote News Research
Stories about Regeneron Pharmaceuticals, Inc.
 
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Regeneron Pharmaceuticals: 52-Week High Recently Eclipsed (REGN)
February 15, 2011
from Comtex SmarTrend® News Briefs
After Yesterday's Rally of 6.80%, Regeneron Pharmaceuticals Shares Could Potentially Pullback (REGN)
February 15, 2011
from Comtex SmarTrend® News Briefs
Barclays maintains an 'Overweight' on Regeneron Pharma (REGN); Strong Showing For VTE in Miami
February 14, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6291219 for the full story. Read More
from StreetInsider.com News Articles
Earnings Alert: Regeneron Pharmaceuticals is Expected to Beat the Street Consensus When It Reports Earnings (REGN)
February 14, 2011
from Comtex SmarTrend® News Briefs
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Angiogenesis Mtg Highlights Robust Full Dataset for Multiple VEGF Trap-Eye Trials
February 14, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6287819 for the full story. Read More
from StreetInsider.com News Articles
Regeneron Pharmaceuticals Set to Possibly Pullback after Yesterday's Rally of 5.92% (REGN)
February 11, 2011
from Comtex SmarTrend® News Briefs
Recent 52-Week High Exceeded in Shares of Regeneron Pharmaceuticals (REGN)
February 10, 2011
from Comtex SmarTrend® News Briefs
Uptrend Spotted in Shares of Regeneron Pharmaceuticals (REGN)
February 10, 2011
from Comtex SmarTrend® News Briefs
Regeneron Pharmaceuticals Upward Momentum Looks to Continue (REGN)
February 02, 2011
from Comtex SmarTrend® News Briefs
Barclays Maintains an 'Overweight' on Regeneron Pharma (REGN); VEGF Expert Call Highlights Opportunity
February 01, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6249902 for the full story. Read More
from StreetInsider.com News Articles
Regeneron Pharmaceuticals Set to Possibly Pullback after Yesterday's Rally of 1.16% (REGN)
January 28, 2011
from Comtex SmarTrend® News Briefs
SmarTrend's Trend Spotter Sees Continued Upward Momentum on Shares of Regeneron Pharmaceuticals (REGN)
January 26, 2011
from Comtex SmarTrend® News Briefs
Regeneron Pharmaceuticals Set to Possibly Pullback after Yesterday's Rally of 5.12% (REGN)
January 17, 2011
from Comtex SmarTrend® News Briefs
Regeneron Pharmaceuticals Looks to Continue to Trade Above its Annual-High Share Price Today (REGN)
January 17, 2011
from Comtex SmarTrend® News Briefs
Watch for Regeneron Pharmaceuticals to Potentially Pullback after Gaining 3.06% Yesterday (REGN)
January 07, 2011
from Comtex SmarTrend® News Briefs
Recent 52-Week High Exceeded in Shares of Regeneron Pharmaceuticals (REGN)
January 07, 2011
from Comtex SmarTrend® News Briefs
Shares of Regeneron Pharmaceuticals Get a Boost, Up 1.3% (REGN)
January 06, 2011
from Comtex SmarTrend® News Briefs
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Positioned for Transformational Year
January 05, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6196939 for the full story. Read More
from StreetInsider.com News Articles
Trials of New Painkiller Halted by FDA Over Concern of Joint Damage
December 28, 2010
Clinical trails by drug companies studying a new painkiller have been halted due to concerns those drugs may be linked to joint damage and the need for total replacement. Read More
from FOXBusiness.com
Trials of New Painkiller Halted by FDA Over Concern of Joint Damage
December 28, 2010
Clinical trails by drug companies studying a new painkiller have been halted due to concerns those drugs may be linked to joint damage and the need for total replacement. Read More
from FOXBusiness.com
FDA places J&J anti-NGF pain drug on clinical hold
December 28, 2010
* AstraZeneca suspended anti-NGF trial earlier this year Read More
category companyNews
from Reuters: Company News
AstraZeneca halts studies on MEDI-578 product
December 28, 2010
LONDON, Dec 28 (Reuters) - British drugmaker AstraZeneca has halted studies on MEDI-578, which treats nerve growth, to assess data on the product further. Read More
category companyNews
from Reuters: Company News
UPDATE 1-Regeneron pain drug put on clinical hold by FDA
December 27, 2010
BOSTON, Dec 27 (Reuters) - Regeneron Pharmaceuticals Inc said on Monday that U.S. regulators placed the company's experimental pain drug for osteoarthritis on clinical hold after a patient in another... Read More
category companyNews
from Reuters: Company News
Bayer and Regeneron report positive results for VEGF Trap-Eye in central retinal vein occlusion and in diabetic macular edema
December 23, 2010
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led... Read More
category Major Drugs , Healthcare , Report
from 1888PressRelease - Full Feed
SmarTrend's Trend Spotter Sees Continued Upward Momentum on Shares of Regeneron Pharmaceuticals (REGN)
December 22, 2010
from Comtex SmarTrend® News Briefs
Regeneron Pharmaceuticals Looks to Continue to Trade Above its Annual-High Share Price Today (REGN)
December 21, 2010
from Comtex SmarTrend® News Briefs
Barclays Maintains an 'Overweight' on Regeneron Pharma (REGN); Positive VEGF-TRAP Data in CRVO & DME
December 21, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6176576 for the full story. Read More
from StreetInsider.com News Articles
Baird Raises Price Target on Regeneron Pharma (REGN), Maintains Neutral Rating
December 20, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6173793 for the full story. Read More
from StreetInsider.com News Articles
UPDATE 1-Regeneron, Bayer eye drug meets late-stage study goal
December 20, 2010
Dec 20 (Reuters) - Regeneron Pharmaceuticals Inc said its eye drug developed with a unit of Bayer AG to treat a common retinal disorder met the main goal of a late-stage study. Read More
category companyNews
from Reuters: Company News
Regeneron Pharma (REGN) and Bayer Announce Positive Top-Line Results in COPERNICUS for VEGF Trap-Eye
December 20, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6172696 for the full story. Read More
from StreetInsider.com News Articles
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here